FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and can be used for treating hypogonadotropic hypogonadism in patients. That is ensured by administering gonadorelin acetate intranasally in dose of 1–20 mcg in pulsed mode once every 60–90 minutes. Also disclosed are a method of administering gonadorelin acetate and a spray for treating hypogonadotropic hypogonadism.
EFFECT: group of inventions provides treating hypogonadotropic hypogonadism by administering gonadorelin acetate in a low dosage in the form of spray intranasally in pulsed mode, providing the active substance delivery within the framework of physiological secretion.
3 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING HYPOGONADOTROPIC HYPOGONADISM, NASAL SPRAY AS METHOD FOR ADMINISTERING PEPTIDE COMPLEX "MH-GNDR-19-21" IN TREATING HYPOGONADOTROPIC HYPOGONADISM | 2023 |
|
RU2829548C1 |
| METHOD FOR TREATMENT OF ADOLESCENT HYPOGONADOTROPIC HYPOGONADISM IN EXPERIMENT | 2020 |
|
RU2750713C1 |
| METHOD OF PREDICTION OF CLINICAL EFFECTIVENESS OF TREATMENT WITH CHORIONIC GONADOTROPIN IN MALES WITH HYPOGONADISM | 2015 |
|
RU2604681C1 |
| METHOD OF TREATING SECONDARY HYPOGONADISM IN MALES | 1995 |
|
RU2117446C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF PITUITARY INCIDENTALOMA | 2023 |
|
RU2822656C1 |
| METHOD FOR MODELLING MALE HYPOGONADOTROPIC HYPOGONADISM | 2020 |
|
RU2749477C1 |
| METHOD FOR PREDICTING PARTIAL AGE-CAUSED ANDROGENIC DEFICIENCY (PADAM) | 2002 |
|
RU2231289C2 |
| METHOD FOR INTEGRATED TREATMENT OF MALE NORMOGONADOTROPIC INFERTILITY | 2012 |
|
RU2480256C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS OF HUMAN CHORIONIC GONADOTROPIN THERAPY OF HYPOGONADOTROPIC AND NORMOGONADOTROPIC HYPOGONADISM | 2012 |
|
RU2519743C1 |
| DIAGNOSTIC METHOD OF CENTRAL HYPOGONADISM IN FEMALES | 2019 |
|
RU2710539C1 |
